About Xpress Biologics
Xpress Biologics is a company based in Liege (Belgium) founded in 2014 was acquired by Polyplus Transfection in December 2022. The company has 51 employees as of December 31, 2022. Xpress Biologics offers products and services including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools. Xpress Biologics operates in a competitive market with competitors including KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
- Headquarter Liege, Belgium
- Employees 51 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Xpress Biologics
-
Annual Revenue
Not available
-
Net Profit
-$916.94 K (USD)-1557as on Dec 31, 2022
-
EBITDA
-$92.07 K (USD)-115as on Dec 31, 2022
-
Latest Funding Round
Not available
-
Investors
Polyplus Transfection
& 1 more
-
Employee Count
51
as on Dec 31, 2022
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Xpress Biologics
Xpress Biologics offers a comprehensive portfolio of products and services, including Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.
Develops and produces recombinant proteins for research and clinical use.
Produces plasmid DNA for vaccine and therapeutic applications.
Manufactures antibody fragments for diagnostics and treatments.
Creates tools for quality control in biologics production.
Funding Insights of Xpress Biologics
Detailed funding history for Xpress Biologics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Xpress Biologics
Xpress Biologics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Polyplus Transfection and ARCHIMED.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare industries are funded and supported globally by ARCHIMED.
|
Locked | Locked | Locked | |
|
Transfection Solutions for Healthcare and Life Sciences organizations
|
Locked | Locked | Locked |
Investor details for Xpress Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Xpress Biologics
Investment portfolio details for Xpress Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Xpress Biologics
Detailed financials for Xpress Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Xpress Biologics Comparisons
Peer comparison for Xpress Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Xpress Biologics
Xpress Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as KBI Biopharma, EirGenix, Aldevron, Arranta Bio and Ovagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of protein formulation, process & cell line development, and cGMP services
|
|
| Locked | Locked | Locked |
Biologics development and manufacturing services are offered by EirGenix.
|
|
| Locked | Locked | Locked |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| Locked | Locked | Locked |
Developer of therapeutics for microbiome based diseases
|
|
| Locked | Locked | Locked |
Provider of germ-free and specific pathogen free production of eggs for vaccine and antibody manufacturing services
|
|
| Locked | Locked | Locked |
Vaccines and biologics are developed and manufactured by IDT Biologika.
|
Detailed competitors of Xpress Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Xpress Biologics
Complete news archive for Xpress Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xpress Biologics
Xpress Biologics was founded in 2014.
Xpress Biologics is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
As of Dec 31, 2022, the latest employee count at Xpress Biologics is 51.
Xpress biologics is a contract research organisation offering services in the following areas designing of protein purification system (bacteria and yeasts), process development and manufacturing of new biologics (recombinant proteins, antibody fragments, and plasmid DNA), biosimilars and biobetters, and the management of the pre-clinical and clinical trials management of the GMP manufacturing. The company provides these services to human and veterinary healthcare markets and diagnostic markets. Additionally, the company also provides services in analytical testing.
Xpress Biologics's top competitors include KBI Biopharma, Aldevron and Ovagen.
Xpress Biologics offers Recombinant Protein Manufacturing, Plasmid DNA Manufacturing, Antibody Fragment Manufacturing, and Development of Analytical Tools.
Xpress Biologics has 2 investors. Key investors include Polyplus Transfection, and ARCHIMED.